Sanofi shares came under pressure after the company reported a sharp drop in second-quarter net profit, even as business performance improved and the French drugmaker lifted its outlook for fiscal 2026. The results showed a clear split between accounting profit—down year over year—and underlying “business net income,” which rose on strong revenue growth, including continued momentum in Dupixent.
The company now expects sales to grow by approximately 10% in 2026 at constant exchange rates, forecasting business earnings per share to increase slightly faster than sales. Sanofi previously guided for high-single-digit sales growth and business earnings per share growth modestly ahead of sales.
Key takeaways
- Profit was weaker: Sanofi reported second-quarter net income attributable to equity holders of €343 million, down from €3.939 billion a year earlier.
- Underlying earnings improved: Business net income rose to €2.501 billion, up 28.9% year over year.
- Revenue acceleration: Second-quarter net sales increased to €11.597 billion, up 17.8%, supported by pharmaceutical launches and acquisitions.
- Catalyst and guidance update: Dupixent sales surged 37.6% year over year, while Sanofi upgraded its fiscal 2026 sales and business EPS outlook.
- Implication for investors: The company’s earnings quality—strong business earnings despite lower net profit—will likely remain central to how markets assess its earnings trajectory.
What drove the second-quarter results
Sanofi’s headline profitability declined sharply in the second quarter. Net income attributable to equity holders fell to €343 million from €3.939 billion in the prior-year period. Basic earnings per share dropped to €0.29 from €3.24.
However, on a continuing operations basis, Sanofi reported net income of €377 million, or €0.29 per share, compared with €1.236 billion or €1.02 per share in the year-ago quarter.
In contrast, the company’s underlying performance improved materially. Business net income totaled €2.501 billion, up 28.9% from €1.940 billion. Business earnings per share increased by 31.4% to €2.09 from €1.59.
Revenue growth also came in strong. Net sales rose to €11.597 billion, an increase of 17.8% from €9.994 billion a year earlier. Sanofi said the sales increase was driven by pharmaceutical launches, contributions from recent acquisitions, and performance in Dupixent. Dupixent sales accelerated to a 37.6% year-over-year gain.
How investors are likely to interpret the guidance upgrade
Sanofi’s upgraded outlook is the clearest forward-looking signal in the update. For fiscal 2026, the company now expects sales growth of approximately 10% at constant exchange rates. It also projects business earnings per share to expand slightly faster than sales.
That compares with prior guidance for sales growth in the high single digits and business EPS growth that was expected to run slightly ahead of sales at constant exchange rates.
Investors may view the upgrade as confirmation that growth drivers—particularly Dupixent and the impact of new launches and acquisitions—are sustaining momentum into next year. At the same time, the sharp decline in net profit in the quarter underscores that investors will likely scrutinize the difference between statutory net income and business earnings when assessing consistency and risk.
Market reaction: growth versus profit optics
Sanofi’s quarter presented a mixed picture: rapid growth in sales and business earnings, alongside a steep drop in reported net profit. The divergence matters because markets often react more to earnings power than to revenue growth alone, especially for large-cap healthcare companies where investors track both cash generation and earnings quality.
By tying the guidance upgrade to business earnings per share growth slightly faster than sales, Sanofi is effectively signaling that underlying profitability is improving at a rate that can outpace top-line expansion. Still, the reported net profit decline—reflected in both net income attributable to equity holders and basic earnings per share—may keep analysts focused on what is driving the gap, including any items impacting statutory results.
What to watch next
With Sanofi now targeting around 10% sales growth at constant exchange rates for 2026 and slightly faster business EPS growth, the next read-through for investors will be whether Dupixent’s strength and the contribution from launches and acquisitions translate into continued business earnings momentum. Traders and long-term investors will also watch subsequent quarterly reporting to see if the statutory-to-business earnings gap narrows or widens.
